These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1009 related items for PubMed ID: 21043546

  • 1. Tdap5 vaccine (Covaxis): a review of its use as a single-booster immunization for the prevention of tetanus, diphtheria, and pertussis in children (aged 4 years), adolescents, and adults.
    Scott LJ.
    BioDrugs; 2010 Dec 01; 24(6):387-406. PubMed ID: 21043546
    [Abstract] [Full Text] [Related]

  • 2. Spotlight on Tdap₅ vaccine (Covaxis®) as a single-booster immunization for the prevention of tetanus, diphtheria, and pertussis: in children (aged ≥4 years), adolescents, and adults.
    Scott LJ.
    Paediatr Drugs; 2011 Apr 01; 13(2):133-5. PubMed ID: 21351814
    [Abstract] [Full Text] [Related]

  • 3. Combined, reduced-antigen content tetanus, diphtheria, and acellular pertussis vaccine (Boostrix): a review of its use as a single-dose booster immunization in individuals aged 10-64 years in the US.
    Plosker GL.
    BioDrugs; 2009 Apr 01; 23(4):253-67. PubMed ID: 19697967
    [Abstract] [Full Text] [Related]

  • 4. Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization.
    McCormack PL.
    Drugs; 2012 Sep 10; 72(13):1765-91. PubMed ID: 22931522
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Safety and immunogenicity of SIIPL Tdap, a new tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, in healthy subjects 4-65 years of age: A Phase II/III randomized, observer-blinded, active controlled, multicenter clinical study in Germany.
    Aydin I, May M, Pisano F, Mpofu-Maetzig N, Grode L, Parekh S, Pujari P, Shewale S, Desai S, Sharma H, Rao H, Gautam M, Gairola S, Shaligram U.
    Vaccine; 2023 Nov 02; 41(46):6810-6819. PubMed ID: 37827966
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Reduced-antigen, combined diphtheria, tetanus, and acellular pertussis vaccine (Boostrix): a review of its use as a single-dose booster immunization.
    Frampton JE, Keating GM.
    BioDrugs; 2006 Nov 02; 20(6):371-89. PubMed ID: 17176125
    [Abstract] [Full Text] [Related]

  • 10. Reduced-antigen, combined diphtheria-tetanus-acellular pertussis vaccine, adsorbed (Boostrix) US formulation): use as a single-dose booster immunization in adolescents aged 10-18 years.
    Frampton JE, Keam SJ.
    Paediatr Drugs; 2006 Nov 02; 8(3):189-95; discussion 196. PubMed ID: 16774298
    [Abstract] [Full Text] [Related]

  • 11. Spotlight on DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa).
    Dhillon S.
    BioDrugs; 2010 Oct 01; 24(5):299-302. PubMed ID: 20795752
    [Abstract] [Full Text] [Related]

  • 12. Safety and immunogenicity of tetanus-diphtheria-acellular pertussis vaccine administered to children 10 or 11 years of age.
    Marshall GS, Pool V, Greenberg DP, Johnson DR, Sheng X, Decker MD.
    Clin Vaccine Immunol; 2014 Nov 01; 21(11):1560-4. PubMed ID: 25230939
    [Abstract] [Full Text] [Related]

  • 13. Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study.
    Kovac M, Kostanyan L, Mesaros N, Kuriyakose S, Varman M.
    Hum Vaccin Immunother; 2018 Nov 01; 14(8):1977-1986. PubMed ID: 29630439
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine.
    Tomovici A, Barreto L, Zickler P, Meekison W, Noya F, Voloshen T, Lavigne P.
    Vaccine; 2012 Mar 30; 30(16):2647-53. PubMed ID: 22353673
    [Abstract] [Full Text] [Related]

  • 16. Two consecutive randomized controlled pertussis booster trials in children initially vaccinated in infancy with an acellular vaccine: The first with a five-component Tdap vaccine to 5-year olds and the second with five- or monocomponent Tdap vaccines at age 14-15 years.
    Carlsson RM, Gustafsson L, Hallander HO, Ljungman M, Olin P, Gothefors L, Nilsson L, Netterlid E.
    Vaccine; 2015 Jul 17; 33(31):3717-25. PubMed ID: 26057135
    [Abstract] [Full Text] [Related]

  • 17. A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults.
    Thierry-Carstensen B, Jordan K, Uhlving HH, Dalby T, Sørensen C, Jensen AM, Heilmann C.
    Vaccine; 2012 Aug 10; 30(37):5464-71. PubMed ID: 22776216
    [Abstract] [Full Text] [Related]

  • 18. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults.
    Mertsola J, Van Der Meeren O, He Q, Linko-Parvinen A, Ramakrishnan G, Mannermaa L, Soila M, Pulkkinen M, Jacquet JM.
    Clin Infect Dis; 2010 Sep 15; 51(6):656-62. PubMed ID: 20704493
    [Abstract] [Full Text] [Related]

  • 19. Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults.
    Brandon D, Kimmel M, Kuriyakose SO, Kostanyan L, Mesaros N.
    Vaccine; 2018 Oct 08; 36(42):6325-6333. PubMed ID: 30197282
    [Abstract] [Full Text] [Related]

  • 20. A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults.
    Leroux-Roels G, Lattanzi M, Solis CD, Contorni M, Costantini M, Moraschini L, Bardelli M, Bertholet S, Borgogni E, Buricchi F, Cantisani R, Faenzi E, Finco O, Leuzzi R, Pizza M, Rosa D, Schiavetti F, Seubert A, Spensieri F, Volpini G, Zedda L, Giudice GD, Galgani I.
    Hum Vaccin Immunother; 2018 Jan 02; 14(1):45-58. PubMed ID: 29172945
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.